
Opinion|Videos|December 23, 2024
Final Thoughts: The Spesolimab and GPP Flare Reduction
Key Takeaways
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
The Weekly Roundup: December 1-5
3
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
4
Experts See Promise in AI for Atopic Dermatitis Care
5

















